Dendright Pty. Ltd., J&J autoimmune news

Dendright partnered with the Janssen-Cilag Pty. Ltd. Australian unit of Johnson & Johnson and received a seed grant to fund preclinical development of Dendright's technology to treat rheumatoid arthritis. The company said the ability of dendritic cells to induce T cell activation or tolerance can be controlled by the manipulation of NF-kappa B (NF-kB) and the protein v-rel reticuloendotheliosis viral oncogene homolog B (RELB). Dendright is developing a liposome product to treat RA that encapsulates an inhibitor of NF-kB and an antigen to silence T cells in an "antigen-specific manner." Details were not disclosed. ...